Comparison · NCT04120194-deaths
NanoFlu vs Fluzone Quadrivalent: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. NanoFlu vs Fluzone Quadrivalent: deaths from any cause. Trial comparisons, record NCT04120194-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04120194-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.006 | 0.00304 | 0.0118 | wilson | |
| Risk in group 2 | 0.00607 | 0.00308 | 0.0119 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0000637 | -0.00663 | 0.00646 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.989 | 0.372 | 2.63 | log | |
| Odds ratio, group 1 over group 2 | 0.989 | 0.37 | 2.64 | log | |
| Number needed to treat, for one fewer death from any cause on NanoFlu than on Fluzone Quadrivalent | 15,700 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | NanoFlu | NanoFlu will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.~NanoFlu: Investigational quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season. | 8 | 1,333 | EG000 |
| Group 2 | Fluzone Quadrivalent | Fluzone Quadrivalent will be administered as a single dose (0.5 mL) in the arm muscle on Day 0.~Fluzone Quadrivalent: Licensed quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season. | 8 | 1,319 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- 1 year
Source ClinicalTrials.gov
Trial
- Title
- Phase 3 Pivotal Trial of NanoFlu™ in Older Adults
- NCT number
- NCT04120194
- Phases
- PHASE3
- Conditions
- Influenza, Human
- Interventions
- NanoFlu, Fluzone Quadrivalent
- Lead sponsor
- Novavax
- Results first posted
- 2023-05-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04120194?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04120194-deaths